Abstracts tagged "rheumatoid arthritis"

Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Jie An¹, Bhanupriya Madarampalli², Xizhang Sun², Lena Tanaka³, Erika H. Noss², Joshua Woodward⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶University of Washington, Seattle, WA
Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting
CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Kotona Furuyama¹, Yuya Kondo¹, Masaru Shimizu², Iizuka Akira¹, Masahiro Yokosawa¹, Seiji Segawa¹, Hiroto Tsuboi¹, Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
Abstract Number: 1073 • 2018 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Takuya Hirai², Hiroshi Tsushima², Ken Yamaji³, Naoto Tamura³ and Iwao Sekigawa⁴, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ³Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan
Background/Purpose: Aberrant angiogenesis has been considered as one of important factors for pathogenesis of rheumatoid arthritis (RA). Several angiogenetic mediators are reported to be massively…
Abstract Number: 50 • 2018 ACR/ARHP Annual Meeting
Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis
Chrong-Reen Wang¹, Shih-Yao Chen², Yu-Ting Lo³, Yu-Chi Chou⁴, Ming-Fei Liu¹, Chao-Liang Wu⁵ and Ai-Li Shiau³, ¹Internal Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Core Facility for Manipulation of Gene Function, Academia Sinica, Taipei, Taiwan, ⁵Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Aberrantly higher expression of long non-coding RNAs (lncRNAs) in synovial fibroblasts (SFs) plays pathogenic roles in rheumatoid joint. Studying the effects on knocking down…
Abstract Number: 1076 • 2018 ACR/ARHP Annual Meeting
Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis
Mingyo Kim, Hyun Min Jeon, Hae Sook Noh, Sang Mi Yi and Sang-Il Lee, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)
Background/Purpose: The C2 domain is a Ca2+-dependent membrane-targeting motif found in many cellular proteins involved in signal transduction or inflammatory pathway. However, the effects of…
Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Patrick Durez^2,3, Adrien Nzeusseu Toukap⁴ and Maria Stoenoiu⁵, ¹Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
Abstract Number: 55 • 2018 ACR/ARHP Annual Meeting
Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice
Tadashi Okano¹, Kentaro Inui², Hideki Ueyama³, Kumi Orita³, Tatsuya Koike⁴ and Hiroaki Nakamura², ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Adipose derived stem cell (ADSC) is one of the stem cells produced by adipose tissue which can be collected easily and in large quantities.…
Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Jeffrey R. Curtis¹, Jürgen Wollenhaupt², Katerina Chatzidionysiou³, Sander W. Tas⁴, Lisy Wang⁵, Harry Shi⁶, María Montoro⁷, Petra Neregård⁸, Palle Dahl⁹ and Vassilis Tsekouras¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Madrid, Spain, ⁸Pfizer Inc, Stochholm, Sweden, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Athens, Greece
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…

1
2
3
…
19
Next Page »